Clinical trials: Acromegaly
Acromegaly
Study in Polish Acromegalic Patients Treated With Somatuline Autogel
The purpose of this study is to evaluate over the 24 month prospective follow up - in everyday clinical practice - resource utilization and effectiveness of the treatment of acromegalic patients in Poland with Somatuline Autogel…
- Trial name
- NCT01333384
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Ipsen
Acromegaly
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
- Trial name
- NCT07583563
- Testing
- Octreotide subcutaneous depot
- Where
- 7 sites in Germany, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Camurus AB
Acromegaly, Pituitary Tumor
The Observational Study of Growth Hormone-secreting Pituitary Tumors
The major purpose of this study is to evaluate the changes of multiple organs in patients with growth hormone-secreting pituitary tumors before and after surgery.
- Trial name
- NCT01368133
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Acromegaly
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
The purpose of this study is to compare the effectiveness of lanreotide autogel to placebo after a single injection. Effectiveness and safety were then also assessed following four fixed-dose injections and after one year of…
- Trial name
- NCT00234572
- Testing
- Lanreotide (Autogel formulation)
- Where
- 29 sites in United States, Czechia and 6 more
- Volunteers
- 108 people
- Sponsor
- Ipsen
Acromegaly
Acromegaly: Balance, Falls and Fracture Risk
The goal of this observational, cross-sectional study is to study bone quality, joint quality and fall risk in acromegalic patients, compared with healthy controls.
- Trial name
- NCT05752825
- Testing
- HR-pQCT, DXA scan, Bone microindentation
- Where
- Denmark
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Christian Alexander H Rosendal
Acromegaly
Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
The study is designed to investigate the safety, tolerability and efficacy of DG3173 in untreated acromegaly patients. Twenty patients received ascending single doses of DG3173 and one dose of octreotide, the current gold…
- Trial name
- NCT02235987
- Testing
- octreotide, DG3173
- Volunteers
- 20 people
- Sponsor
- Aspireo Pharmaceuticals Limited
Acromegaly
The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
This study is designed to assess the effect of the different continuous s.c. infusion treatments on the human growth hormone (hGH) levels in untreated acromegalic patients in comparison to a standard dose of octreotide.
- Trial name
- NCT02217800
- Testing
- saline, DG3173, octreotide
- Volunteers
- 8 people
- Sponsor
- Aspireo Pharmaceuticals Limited
Acromegaly, Nonfunctioning Pituitary Adenoma
Direct Versus Video Laryngoscopy in Patients With Acromegaly
Acromegaly is associated with craniofacial skeletal changes and upper airway soft tissue hypertrophy, which may increase the risk of difficult laryngoscopy and tracheal intubation.
- Trial name
- ACRO-VL (NCT07659912)
- Volunteers
- 40 people
- Sponsor
- Muzaffer GENCER
Pituitary Tumor
PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome…
- Trial name
- PITUICARE-Lyon (NCT02854228)
- Where
- France
- Volunteers
- 1,300 people
- Sponsor
- Hospices Civils de Lyon
Acromegaly
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial (OPTMAL; NCT03252353), oral octreotide capsules demonstrated sustained biochemical…
- Trial name
- MPOWERED (NCT02685709)
- Testing
- Octreotide capsules
- Where
- 53 sites in United States, Austria and 11 more
- Volunteers
- 146 people
- Sponsor
- Chiasma, Inc.
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with…
- Trial name
- PATHFNDR-2 (NCT05192382)
- Testing
- Paltusotine
- Where
- 57 sites in United States, Argentina and 13 more
- Volunteers
- 111 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Cushing's Disease, Acromegaly
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin.
- Trial name
- NCT02060383
- Testing
- Pasireotide s.c., Sitagliptin, Liraglutide
- Where
- 43 sites in United States, Belgium and 10 more
- Volunteers
- 249 people
- Sponsor
- Novartis Pharmaceuticals
Cushing Syndrome, Acromegaly
Muscle in Acromegaly and Cushing's Syndrome
Cushing's syndrome (CS) and acromegaly determine myopathy and muscle weakness which persist long-term after control of hormone excess.
- Trial name
- MAC (NCT03673761)
- Testing
- MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Acromegaly
Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
Treatment of acromegaly with somatostatin analogs (SA) is well-established and are primarily used after insufficient surgical intervention, but also as primary medical treatment in selected patients.
- Trial name
- NCT01618513
- Testing
- Sandostatin® LAR
- Where
- Denmark
- Volunteers
- 84 people
- Sponsor
- University of Aarhus
Acromegaly
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.
- Trial name
- NCT00216398
- Testing
- Lanreotide (Autogel formulation)
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- Ipsen
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly, Nonfunctioning Pituitary Tumor
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors
The purpose of the study is to evaluate the Calcium homeostasis in adult patients with uncontrolled acromegaly. The measurements will be repeated 3-6 months after the treatment of acromegaly (surgical or medical).
- Trial name
- NCT01568359
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Emory University
Acromegaly
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
The purpose of the study is to assess the efficacy of an extended injection interval schedule of lanreotide Autogel 120 mg in acromegalic subjects who are biochemically controlled on long term treatment with octreotide LAR 10 or…
- Trial name
- LEAD (NCT00701363)
- Testing
- Lanreotide Autogel 120 mg
- Where
- 44 sites in Brazil, Denmark and 12 more
- Volunteers
- 124 people
- Sponsor
- Ipsen
Acromegaly, Muscle Dysfunction
Rehabilitation Program in Patients With Acromegaly
Acromegaly is chronic, systemic and highly disabling disease. People with Acromegaly show a significant reduction in peripheral muscle strength associated with a loss resistance and lethargy.
- Conditions
- Acromegaly, Muscle Dysfunction, Physical Activity, Exercise
- Trial name
- NCT03710499
- Testing
- Physical activity
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Centro Universitário Augusto Motta
Acromegaly
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00658879
- Testing
- Somavert (Pegvisomant)
- Volunteers
- 251 people
- Sponsor
- Pfizer